7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment

@article{Korben20157MethoxytacrinepAnisidineHA,
  title={7-Methoxytacrine-p-Anisidine Hybrids as Novel Dual Binding Site Acetylcholinesterase Inhibitors for Alzheimer’s Disease Treatment},
  author={J. Kor{\'a}be{\vc}n{\'y} and M. Andr{\vs} and E. Nepovimova and R. Dolezal and K. Babkova and A. Horova and D. Maliň{\'a}k and E. Mezeiova and L. G{\'o}recki and V. Sepsova and M. Hrabinov{\'a} and O. Soukup and D. Jun and K. Ku{\vc}a},
  journal={Molecules},
  year={2015},
  volume={20},
  pages={22084 - 22101}
}
Alzheimer’s disease (AD) is a debilitating progressive neurodegenerative disorder that ultimately leads to the patient’s death. Despite the fact that novel pharmacological approaches endeavoring to block the neurodegenerative process are still emerging, none of them have reached use in clinical practice yet. Thus, palliative treatment represented by acetylcholinesterase inhibitors (AChEIs) and memantine are still the only therapeutics used. Following the multi-target directed ligands (MTDLs… Expand
Novel tacrine-tryptophan hybrids: Multi-target directed ligands as potential treatment for Alzheimer's disease.
...
1
2
3
4
...

References

SHOWING 1-10 OF 72 REFERENCES
Multifunctional tacrine derivatives in Alzheimer's disease.
Design, synthesis and in vitro testing of 7-methoxytacrine-amantadine analogues: a novel cholinesterase inhibitors for the treatment of Alzheimer’s disease
A resurrection of 7-MEOTA: a comparison with tacrine.
[Intended pharmacotherapeutical approaches of Alzheimer's disease therapy].
  • J. Korábečný, E. Hruba, +6 authors K. Kuča
  • Psychology, Medicine
  • Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti
  • 2012
...
1
2
3
4
5
...